Last reviewed · How we verify
SB649868
At a glance
| Generic name | SB649868 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Disturbed Sleep Model Study. (PHASE1)
- 15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects. (PHASE1)
- Bioequivalence and Food Effect Study in Healthy Volunteers (PHASE1)
- Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug (PHASE1)
- A Single-centre Open Label Study to Investigate the Effect of Repeat Doses of SB-649868 on the Pharmacokinetics of Simvastatin and Atorvastatin in Healthy Male Volunteers. (PHASE1)
- Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers (PHASE1)
- A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderly and Female Population (PHASE1)
- To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB649868 CI brief — competitive landscape report
- SB649868 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI